presentation - lab on a chip - dale athey

8/7/2019 Presentation - Lab on a Chip - Dale Athey

1/28

Lab on a chip how microdiagnostics

are revolutionising healthcare

NETPark Incubator 1st

June 2009

Dale Athey

CEO, Orla Protein Technologies Ltd


2/28

There are several major global drivers

forin vitro and molecular diagnostics

Increase in

Chronic Disease

Availability ofhigh

value diagnostics

Growth indecentralised

healthcare

An aging population


3/28

How can we successfully capture some

of the commercial opportunity ?


4/28

Whilst attractive the market is highly

competitive


5/28

We can learn from the experience of

others


6/28

I would like to share my experience with

Orla Protein Technologies

1.

Orla background

2.

Diagnostics

3.

Commercialisationissues


7/28

1.Orla background


8/28

Orla is a spinout from Newcastle University

1. Orla background


9/28

Opportunity

the highest growth rates will

be in the convergence

between bio- and nano-technologies in the

healthcare and

pharmaceutical sectors

1. Orla background

Source Cientifica Ltd: Nanotechnology

Opportunity Report, 3rd Edition. June

2008


10/28

Orla design, and manufacture proteins for

surface applications

5nm

gene bacteria purified proteinsurface

1. Orla background


11/28

The platform has wide application

1. Orla background


12/28

1. Orla background

Convergence ofelectronics and biotechnology


13/28

2.Diagnostics


14/28

2. Diagnostics

Partnership with Japan Radio Company


15/28

4 Millionpieces permonth

2. Diagnostics

Manufacturing capability


16/28

LAN

PHS

ETC ETC

W-CDMA

SAW

GPS

GPS IP

SSLPHS

26GHz P-MPIP

*+]):$

*+]0ESV

VICS

2. Diagnostics

Communications expertise


17/28

SAW

2. Diagnostics

Joint venture on a next generation

diagnostics platform


18/28

2. Diagnostics

Prototypes already available


19/28

2. Diagnostics

Other benefits of technology


20/28

Technology Strategy Board Funding

New rapid testing device will target respiratory disease24 October 2008

Newcastle-Upon-Tyne UK. Newcastle-based nano-

biotechnology firm Orla Protein Technologies Ltd,

has secured a government investment of nearly

700,000 to help its wireless electronic technology

for the rapid detection of respiratory viruses such

as Respiratory Syncitial Virus (RSV) and Influenza

(Flu).

The 1.1M development project VIRASENS, is

part-funded by a collaborative R&D grant from theTechnology Strategy Board

2.Diagnostics


21/28

3.

Commercialisation

issues


22/28

Micro diagnostics and miniaturisation

have a role

3. Commercialisation issues


23/28

Its a long journey from the University

bench tocommercial success



24/28

Universities

Degree ofCommercial Opportunity

Commercial risk

Commercial interest

Science Technology Business



25/28

Technology is only a small part of

commercialisation

Technology Risk does it work ?

Data Risk does it work in application area ?

Product Risk can you manufacture ?

Commercialisation Risk reimbursement, regulatory



26/28

To bring a new biomarker-based

diagnostic test to market takes

an estimated 3 years and $45-

50Mto complete outcome

studies. From first investment to

revenues this estimate rises to

$70-100M


Howwill you finance the development ?

VC panel comment at CHI Molecular medicine

Triconference in San Fransisco, 2009


27/28

We can successfully capture some of

the commercial opportunity ?

need to think about

business model not just

technology

Yes..but


28/28

Thank you for your attention

[email protected]

www.orlaproteins.com

presentation - lab on a chip - dale athey

Documents